Acebutolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Aldesleukin.
Alclometasone
Alclometasone may decrease the antineoplastic activities of Aldesleukin.
Advertisement
Aldosterone
Aldosterone may decrease the antineoplastic activities of Aldesleukin.
Aliskiren
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Aliskiren.
Amcinonide
Amcinonide may decrease the antineoplastic activities of Aldesleukin.
Advertisement
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Aldesleukin.
Amifostine Anhydrous
The risk or severity of adverse effects can be increased when Amifostine is combined with Aldesleukin.
Amiloride
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiloride.
Advertisement
Amiodarone
The risk or severity of adverse effects can be increased when Amiodarone is combined with Aldesleukin.
Amlodipine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.
Amobarbital
Amobarbital may increase the hypotensive activities of Aldesleukin.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Aldesleukin.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Aldesleukin.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Amyl Nitrite.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Aldesleukin.
Androstenedione
Androstenedione may decrease the antineoplastic activities of Aldesleukin.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Aldesleukin.
Apraclonidine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Apraclonidine.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Aldesleukin.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Aldesleukin.
Atenolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Atenolol.
Atorvastatin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Atorvastatin.
Azilsartan
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Aldesleukin.
Barbital
Barbital may increase the hypotensive activities of Aldesleukin.
Beclomethasone Dipropionate
Beclomethasone dipropionate may decrease the antineoplastic activities of Aldesleukin.
Benazepril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.
Bendroflumethiazide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendroflumethiazide.
Bepridil
The risk or severity of adverse effects can be increased when Bepridil is combined with Aldesleukin.
Betamethasone
Betamethasone may decrease the antineoplastic activities of Aldesleukin.
Betaxolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Aldesleukin.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Aldesleukin.
Bisoprolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Aldesleukin.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Aldesleukin.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Aldesleukin.
Bretylium
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bretylium.
Brimonidine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Brimonidine.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Aldesleukin.
Budesonide
Budesonide may decrease the antineoplastic activities of Aldesleukin.
Bumetanide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Aldesleukin.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aldesleukin.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Aldesleukin.
Canagliflozin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan cilexetil.
Captopril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.
Carteolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carteolol.
Carvedilol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Carvedilol.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Aldesleukin.
Chlorothiazide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Aldesleukin.
Chlorthalidone
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorthalidone.
Ciclesonide
Ciclesonide may decrease the antineoplastic activities of Aldesleukin.
Cilazapril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.
Clevidipine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.
Clobetasol
Clobetasol may decrease the antineoplastic activities of Aldesleukin.
Clobetasol Propionate
Clobetasol propionate may decrease the antineoplastic activities of Aldesleukin.
Clobetasone
Clobetasone may decrease the antineoplastic activities of Aldesleukin.
Clocortolone
Clocortolone may decrease the antineoplastic activities of Aldesleukin.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Aldesleukin.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Aldesleukin.
Clonidine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.
Clozapine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Clozapine.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Aldesleukin.
Cortisone Acetate
Cortisone acetate may decrease the antineoplastic activities of Aldesleukin.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Aldesleukin.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Aldesleukin.
Dapagliflozin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.
Deflazacort
Deflazacort may decrease the antineoplastic activities of Aldesleukin.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Aldesleukin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Aldesleukin.
Desonide
Desonide may decrease the antineoplastic activities of Aldesleukin.
Desoximetasone
Desoximetasone may decrease the antineoplastic activities of Aldesleukin.
Desoxycorticosterone acetate
Desoxycorticosterone acetate may decrease the antineoplastic activities of Aldesleukin.
Desoxycorticosterone Pivalate
Desoxycorticosterone Pivalate may decrease the antineoplastic activities of Aldesleukin.
Dexamethasone
Dexamethasone may decrease the antineoplastic activities of Aldesleukin.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexmedetomidine.
Diatrizoate
The risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.
Diatrizoic Acid
The risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Diclofenamide.
Diflorasone
Diflorasone may decrease the antineoplastic activities of Aldesleukin.
Diflucortolone
Difluocortolone may decrease the antineoplastic activities of Aldesleukin.
Difluprednate
Difluprednate may decrease the antineoplastic activities of Aldesleukin.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Aldesleukin.
Digoxin
Digoxin may decrease the cardiotoxic activities of Aldesleukin.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Aldesleukin.
Diltiazem
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Diltiazem.
Dinutuximab
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.
Dipyridamole
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Aldesleukin.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.
Doxazosin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.
Duloxetine
Aldesleukin may increase the orthostatic hypotensive activities of Duloxetine.
Empagliflozin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.
Enalapril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Aldesleukin.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Aldesleukin.
Eplerenone
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eplerenone.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Aldesleukin.
Eprosartan
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Aldesleukin.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Aldesleukin.
Esmolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.
Estrone
Estrone may decrease the antineoplastic activities of Aldesleukin.
Ethacrynate
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.
Ethiodized Oil
The risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.
Felodipine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Aldesleukin.
Fludrocortisone
Fludrocortisone may decrease the antineoplastic activities of Aldesleukin.
Flumethasone
Flumethasone may decrease the antineoplastic activities of Aldesleukin.
Flunisolide
Flunisolide may decrease the antineoplastic activities of Aldesleukin.
Flunisolide Anhydrous (obsolete)
Flunisolide may decrease the antineoplastic activities of Aldesleukin.
Fluocinolone Acetonide
Fluocinolone Acetonide may decrease the antineoplastic activities of Aldesleukin.
Fluocinonide
Fluocinonide may decrease the antineoplastic activities of Aldesleukin.
Fluocortolone
Fluocortolone may decrease the antineoplastic activities of Aldesleukin.
Fluorometholone
Fluorometholone may decrease the antineoplastic activities of Aldesleukin.
FLUPREDNIDENE
Fluprednidene may decrease the antineoplastic activities of Aldesleukin.
Fluprednisolone
Fluprednisolone may decrease the antineoplastic activities of Aldesleukin.
Flurandrenolide
Flurandrenolide may decrease the antineoplastic activities of Aldesleukin.
Fluticasone Furoate
Fluticasone furoate may decrease the antineoplastic activities of Aldesleukin.
Fluticasone propionate
Fluticasone propionate may decrease the antineoplastic activities of Aldesleukin.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Aldesleukin.
Formestane
Formestane may decrease the antineoplastic activities of Aldesleukin.
Fosinopril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.
Furosemide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.
Guanfacine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.
Halcinonide
Halcinonide may decrease the antineoplastic activities of Aldesleukin.
Halobetasol
Ulobetasol may decrease the antineoplastic activities of Aldesleukin.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Aldesleukin.
Hexobarbital
Hexobarbital may increase the hypotensive activities of Aldesleukin.
Hydralazine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydralazine.
Hydrochlorothiazide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrochlorothiazide.
Hydrocortisone
Hydrocortisone may decrease the antineoplastic activities of Aldesleukin.
Hydroflumethiazide
The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Aldesleukin.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Aldesleukin.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Aldesleukin.
Imidapril
The risk or severity of adverse effects can be increased when Imidapril is combined with Aldesleukin.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Aldesleukin.
Indapamide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.
Indoramin
The risk or severity of adverse effects can be increased when Indoramin is combined with Aldesleukin.
Interferon Alfa-2a
The risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Aldesleukin.
Interferon Alfa-2b
The risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Aldesleukin.
Interferon Alfa-n3
The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.
Interferon Alfacon-1
The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.
Iodipamide
The risk of a hypersensitivity reaction to Iodipamide is increased when it is combined with Aldesleukin.
Iodixanol
The risk of a hypersensitivity reaction to Iodixanol is increased when it is combined with Aldesleukin.
Iohexol
The risk of a hypersensitivity reaction to Iohexol is increased when it is combined with Aldesleukin.
Iopamidol
The risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.
Iopromide
The risk of a hypersensitivity reaction to Iopromide is increased when it is combined with Aldesleukin.
Iothalamic Acid
The risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.
Ioversol
The risk of a hypersensitivity reaction to Ioversol is increased when it is combined with Aldesleukin.
Ioxilan
The risk of a hypersensitivity reaction to Ioxilan is increased when it is combined with Aldesleukin.
Irbesartan
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Aldesleukin.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Aldesleukin.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoxsuprine.
Isradipine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Isradipine.
Labetalol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.
Lacidipine
Aldesleukin may increase the hypotensive activities of Lacidipine.
Lercanidipine
The risk or severity of adverse effects can be increased when Lercanidipine is combined with Aldesleukin.
Levobunolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Aldesleukin.
Levodopa
Aldesleukin may increase the orthostatic hypotensive activities of Levodopa.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Aldesleukin.
Lisinopril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Aldesleukin.
Lofexidine
The risk or severity of adverse effects can be increased when Lofexidine is combined with Aldesleukin.
Losartan
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.
Loteprednol
Loteprednol may decrease the antineoplastic activities of Aldesleukin.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Aldesleukin.
Mannitol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mannitol.
Mecamylamine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.
Medrysone
Medrysone may decrease the antineoplastic activities of Aldesleukin.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Aldesleukin.
Mepirodipine
The risk or severity of adverse effects can be increased when Barnidipine is combined with Aldesleukin.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Aldesleukin.
Methazolamide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methazolamide.
Methohexital
Methohexital may increase the hypotensive activities of Aldesleukin.
Methyclothiazide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.
Methyldopa
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa.
METHYLDOPA ANHYDROUS
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Aldesleukin.
Methylprednisolone
Methylprednisolone may decrease the antineoplastic activities of Aldesleukin.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Aldesleukin.
Metipranolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metipranolol.
Metolazone
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.
Metoprolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Metoprolol.
Minoxidil
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Minoxidil.
Moexipril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.
Mometasone
Mometasone may decrease the antineoplastic activities of Aldesleukin.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Aldesleukin.
Moxonidine
The risk or severity of adverse effects can be increased when Moxonidine is combined with Aldesleukin.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Aldesleukin.
Nadolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.
Nebivolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.
Nesiritide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nesiritide.
Nicardipine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Aldesleukin.
Nicorandil
Nicorandil may increase the hypotensive activities of Aldesleukin.
Nifedipine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nifedipine.
Nilvadipine
The risk or severity of adverse effects can be increased when Nilvadipine is combined with Aldesleukin.
Nimodipine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.
Nisoldipine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.
Nitrendipine
The risk or severity of adverse effects can be increased when Nitrendipine is combined with Aldesleukin.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Aldesleukin.
Nitroglycerin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.
Nitroprusside
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroprusside.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Aldesleukin.
Olmesartan
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.
Ouabain
Ouabain may decrease the cardiotoxic activities of Aldesleukin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Aldesleukin.
Oxprenolol
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Aldesleukin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldesleukin.
Papaverine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.
Paramethasone
Paramethasone may decrease the antineoplastic activities of Aldesleukin.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Aldesleukin.
Peginterferon Alfa-2a
The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.
Peginterferon Alfa-2b
The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.
Penbutolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Penbutolol.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Aldesleukin.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Aldesleukin.
Perindopril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Perindopril.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Aldesleukin.
Phenobarbital
Phenobarbital may increase the hypotensive activities of Aldesleukin.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Aldesleukin.
Phentolamine
The risk or severity of adverse effects can be increased when Phentolamine is combined with Aldesleukin.
Phentolamine Mesylate
The risk or severity of adverse effects can be increased when Phentolamine is combined with Aldesleukin.
Pindolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Aldesleukin.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Aldesleukin.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Aldesleukin.
Prasterone
Prasterone may decrease the antineoplastic activities of Aldesleukin.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Aldesleukin.
Prazosin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.
Prednicarbate
Prednicarbate may decrease the antineoplastic activities of Aldesleukin.
Prednisolone
Prednisolone may decrease the antineoplastic activities of Aldesleukin.
Prednisone
Prednisone may decrease the antineoplastic activities of Aldesleukin.
Pregnenolone
Pregnenolone may decrease the antineoplastic activities of Aldesleukin.
Primidone
Primidone may increase the hypotensive activities of Aldesleukin.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Aldesleukin.
Propranolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Propranolol.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Aldesleukin.
Quetiapine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.
Quinapril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.
Ramipril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Aldesleukin.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Aldesleukin.
Reserpine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Reserpine.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Aldesleukin.
Rimexolone
Rimexolone may decrease the antineoplastic activities of Aldesleukin.
Riociguat
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Riociguat.
Risperidone
Aldesleukin may increase the hypotensive activities of Risperidone.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Aldesleukin.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Aldesleukin.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Aldesleukin.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Aldesleukin.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Aldesleukin.
Secobarbital
Secobarbital may increase the hypotensive activities of Aldesleukin.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Aldesleukin.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Aldesleukin.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Aldesleukin.
Sotalol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.
Spironolactone
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Spironolactone.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Aldesleukin.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Aldesleukin.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Aldesleukin.
Telmisartan
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.
Terazosin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Aldesleukin.
Thiamylal
Thiamylal may increase the hypotensive activities of Aldesleukin.
Thiopental
Thiopental may increase the hypotensive activities of Aldesleukin.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Aldesleukin.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Aldesleukin.
Timolol
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Timolol.
Timolol Anhydrous
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Timolol.
Tixocortol
Tixocortol may decrease the antineoplastic activities of Aldesleukin.
Tizanidine
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.
Tolazoline
The risk or severity of adverse effects can be increased when Tolazoline is combined with Aldesleukin.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Aldesleukin.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Aldesleukin.
Torsemide
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.
Trandolapril
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Trandolapril.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Aldesleukin.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Aldesleukin.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Aldesleukin.
Triamcinolone
Triamcinolone may decrease the antineoplastic activities of Aldesleukin.
Triamterene
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.
Valsartan
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.
Verapamil
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.
